Hemo Organic

Which are the latest news on Hemo Organic?

Why is Hemo Organic Ltd falling/rising?

As of 19-Jun, Hemo Organic Ltd's stock price is Rs 21.16, unchanged from the previous close but down 4.98% today, underperforming its sector. Despite this short-term decline, the stock has a year-to-date increase of 23.17% and a 103.27% rise over the past year, indicating strong long-term growth.

As of 19-Jun, Hemo Organic Ltd's stock price is currently at Rs 21.16, showing no change from the previous close. However, the stock has experienced a decline of 4.98% today, opening with a loss and touching an intraday low of Rs 21.16. This performance indicates that the stock has underperformed its sector by 5.67%. <BR><BR>In the past week, the stock has fallen by 4.98%, contrasting with a positive return of 1.69% from the Sensex. Despite this short-term decline, Hemo Organic Ltd has shown strong performance over longer periods, with a year-to-date increase of 23.17% and a remarkable 103.27% rise over the past year. <BR><BR>The stock has been trading higher than its moving averages across various time frames, which typically indicates a positive trend. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 57.73% against the 5-day average. However, the stock's erratic trading pattern, having not traded on 5 out of the last 20 days, may contribute to its current volatility and price decline. Overall, while the stock has shown strong long-term growth, recent short-term performance has been negatively impacted by today's significant drop.

How big is Hemo Organic?

As of 10th June, Hemo Organic Ltd has a market capitalization of 7.00 Cr and reported Net Sales of 0.93 Cr with a Net Profit loss of 0.79 Cr over the latest four quarters. Total Assets were 4.70 Cr, with Shareholder's Funds at a loss of 0.15 Cr.

As of 10th June, Hemo Organic Ltd has a market capitalization of 7.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Hemo Organic reported Net Sales of 0.93 Cr. However, the company experienced a loss of 0.79 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. Shareholder's Funds were reported at a loss of 0.15 Cr, while Total Assets amounted to 4.70 Cr.

Who are in the management team of Hemo Organic?

The management team of Hemo Organic includes Dineshbhai S Patel (Chairman & Managing Director), Sonal D Patel (Executive Director), Krushanakant R Patel (Independent Director), Sanjeev Lodha (Additional Independent Director), Siyona Jhnawar (Director), and Nishita Mayank Sanghvi (Company Secretary).

The management team of Hemo Organic includes the following individuals:<BR><BR>1. **Dineshbhai S Patel** - Chairman & Managing Director<BR>2. **Sonal D Patel** - Executive Director<BR>3. **Krushanakant R Patel** - Independent Director<BR>4. **Sanjeev Lodha** - Additional Independent Director<BR>5. **Siyona Jhnawar** - Director<BR>6. **Nishita Mayank Sanghvi** - Company Secretary<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Hemo Organic?

Hemo Organic's peers include Parker Agrochem, Devine Impex, Priya, Nyssa Corp., Evoq Remedies, Enterprise Intl., Mystic Electron, Dhyaani Trade, and Flora Corporatio. Hemo Organic leads with a 1-year return of 102.09%, while Dhyaani Trade has the lowest at -63.19%.

Peers: The peers of Hemo Organic are Parker Agrochem, Devine Impex, Priya, Nyssa Corp., Evoq Remedies, Enterprise Intl., Mystic Electron., Dhyaani Trade, and Flora Corporatio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Flora Corporatio, while Average management risk is found at Parker Agrochem, and the rest have Below Average management risk. Growth ratings show that Priya has Excellent growth, while Average growth is noted at Parker Agrochem, and the rest have Below Average growth. In terms of Capital Structure, Good capital structure is seen at Parker Agrochem and Flora Corporatio, while the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Hemo Organic at 102.09%, while the lowest is Dhyaani Trade at -63.19%. Hemo Organic's 1-year return significantly outperforms all peers. Additionally, the six-month return is negative for Dhyaani Trade, Evoq Remedies, Enterprise Intl., and Mystic Electron.

What does Hemo Organic do?

Hemo Organic Ltd produces and sells white coal and ayurvedic medicines, operating as a Micro Cap company. As of March 2026, it reported net sales of 1 Cr and a net loss of 1 Cr, with a market cap of INR 7 Cr.

Overview:<BR>Hemo Organic Ltd is engaged in the production and sale of white coal and ayurvedic medicines, operating within the Trading & Distributors industry and classified as a Micro Cap company.<BR><BR>History:<BR>Incorporated in August 1992, Hemo Organic Ltd was formerly known as Dinesh Allorga Limited. The company initially focused on manufacturing chemicals but shifted its operations due to a pollution crisis. The latest quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 1 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: -1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 7 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 15 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.87 <BR>Return on Equity: 78.00% <BR>Price to Book: -7.36 <BR><BR>Contact Details:<BR>Address: 8-A Gulnar Chinar-Gulnar Apart, V V Nagar Road Anand Gujarat : 388001 <BR>Tel: 91-2692-248535 <BR>Email: drdineshpatel@rediffmail.com <BR>Website: http://www.hemoorganic.com

Are Hemo Organic Ltd latest results good or bad?

Hemo Organic Ltd's latest results are concerning, showing a net loss of ₹0.51 crores in Q4 FY26, down from a profit of ₹0.37 crores last year, with revenue dropping 61.41% year-on-year. The company faces severe operational challenges and has a negative book value, indicating significant financial instability.

Hemo Organic Ltd's latest results are quite concerning. In Q4 FY26, the company reported a net loss of ₹0.51 crores, a significant decline from a profit of ₹0.37 crores in the same quarter last year. Additionally, revenue plummeted by 61.41% year-on-year to just ₹0.93 crores, marking a troubling trend after three consecutive quarters of zero sales.<BR><BR>The operating margin also deteriorated sharply, falling to -31.18% compared to a positive margin of 5.81% in the previous year. This indicates severe operational distress, as the company is struggling to manage its costs effectively while generating minimal revenue.<BR><BR>Moreover, Hemo Organic has a negative book value of ₹-0.44 per share, reflecting complete equity erosion, and its financial stability is in serious doubt. The company's operational challenges, combined with a lack of institutional investor confidence, suggest a very risky investment environment.<BR><BR>Overall, the results paint a grim picture of Hemo Organic's financial health, indicating that the company is facing significant operational and financial challenges.

Should I buy, sell or hold Hemo Organic Ltd?

When is the next results date for Hemo Organic Ltd?

The next results date for Hemo Organic Ltd is 29 May 2026.

The next results date for Hemo Organic Ltd is scheduled for 29 May 2026.

How has been the historical performance of Hemo Organic?

Hemo Organic has shown significant financial improvement from March 2024 to March 2025, with net sales rising from 0.02 Cr to 2.41 Cr and a turnaround in profitability, achieving a profit after tax of 0.16 Cr. However, the company faces challenges with increased total liabilities, which rose to 4.70 Cr.

Answer:<BR>The historical performance of Hemo Organic shows significant fluctuations in financial metrics over the years, particularly from March 2019 to March 2025.<BR><BR>Breakdown:<BR>Hemo Organic's net sales have seen a notable increase from Mar'24 at 0.02 Cr to Mar'25 at 2.41 Cr, marking a substantial growth. However, the total expenditure also rose sharply to 2.46 Cr in Mar'25 from 0.27 Cr in Mar'24, leading to an operating profit (PBDIT) of 0.02 Cr in Mar'25, a recovery from a loss of 0.25 Cr in the previous year. The profit before tax improved to 0.03 Cr in Mar'25, compared to a loss of 0.26 Cr in Mar'24, and the profit after tax turned positive at 0.16 Cr, reversing from a loss of 0.26 Cr. Despite these improvements, the company's total liabilities increased to 4.70 Cr in Mar'25 from 0.92 Cr in Mar'24, while total assets also rose to 4.70 Cr. The book value per share adjusted to -0.44 in Mar'25, an improvement from -0.91 in Mar'24. The earnings per share (EPS) showed a positive shift to 0.46 in Mar'25 from -0.75 in Mar'24, indicating a recovery in profitability. Overall, while Hemo Organic has made strides in revenue and profit metrics, it continues to face challenges with its liabilities and book value.

Who are the top shareholders of the Hemo Organic?

The top shareholders of Hemo Organic include Dineshbhai Shanabhai Patel with 15.49%, and the Indian Clearing Corporation Limited at 8.08%. Individual investors collectively own 71.11% of the shares, with no institutional holdings or pledged promoter shares reported.

The top shareholders of Hemo Organic include Dineshbhai Shanabhai Patel, who holds the largest stake at 15.49%. The highest public shareholder is the Indian Clearing Corporation Limited, with an ownership of 8.08%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 71.11% of the shares. There are no institutional holdings or pledged promoter shares reported.

Is Hemo Organic overvalued or undervalued?

As of April 1, 2024, Hemo Organic's valuation has shifted to risky due to overvaluation indicated by a PE ratio of 3.75 and poor performance compared to peers, with its stock declining 83.96% over the past three years versus a 49.13% increase in the Sensex.

As of 1 April 2024, Hemo Organic's valuation grade has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, with a PE ratio of 3.75, an EV to EBIT of -5.22, and a PEG ratio of 0.02, all of which suggest significant financial distress and poor profitability.<BR><BR>In comparison to its peers, Hemo Organic's valuation stands out negatively against companies like Altius Telecom, which has a PE ratio of 52.97 and is rated very attractive, and Sagility India, which is rated fair with a PE of 33.73. The stark contrast in these ratios highlights Hemo Organic's struggles within the trading and distribution industry. Additionally, the company's stock performance has lagged behind the Sensex, particularly over the past three years, where it has declined by 83.96% compared to a 49.13% increase in the index.

What is the technical trend for Hemo Organic?

As of June 2, 2025, Hemo Organic's trend is sideways with mixed signals: while the weekly and monthly MACD and Bollinger Bands show mild bullishness, daily moving averages indicate short-term weakness, resulting in overall market indecision.

As of 2 June 2025, the technical trend for Hemo Organic has changed from mildly bullish to sideways. The weekly MACD remains mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands are bullish on both weekly and monthly time frames, which supports the overall bullish sentiment. The KST shows a mixed picture with weekly mildly bullish and monthly mildly bearish readings. Both the Dow Theory and RSI indicate no clear trend. Overall, the current stance is neutral with mixed signals, reflecting indecision in the market.

Has Hemo Organic declared dividend?

No Dividend History Available